Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Citi
US Department of Justice
Colorcon
Covington
Farmers Insurance
Teva
Deloitte
Fish and Richardson
Argus Health

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,105,486

« Back to Dashboard

Summary for Patent: 7,105,486
Title:Abuse-resistant amphetamine compounds
Abstract:The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s): Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Blacksburg, VA), Oberlender; Rob (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA)
Assignee: New River Pharmaceuticals Inc. (Radford, VA)
Application Number:10/858,526
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 7,105,486

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-004 Dec 10, 2007 RX Yes No ➤ Subscribe ➤ Subscribe INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-004 Dec 10, 2007 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-001 Feb 23, 2007 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-005 Dec 10, 2007 RX Yes No ➤ Subscribe ➤ Subscribe INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-002 Feb 23, 2007 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-006 Dec 10, 2007 RX Yes No ➤ Subscribe ➤ Subscribe INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-006 Dec 10, 2007 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Development VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-003 Feb 23, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Dev Llc VYVANSE lisdexamfetamine dimesylate TABLET, CHEWABLE;ORAL 208510-001 Jan 28, 2017 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Shire Dev Llc VYVANSE lisdexamfetamine dimesylate TABLET, CHEWABLE;ORAL 208510-002 Jan 28, 2017 RX Yes No ➤ Subscribe ➤ Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,105,486

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,752 Compounds and compositions for prevention of overdose of oxycodone ➤ Subscribe
7,622,441 Sustained release pharmaceutical compounds to prevent abuse of controlled substances ➤ Subscribe
7,674,774 Abuse-resistant amphetamine prodrugs ➤ Subscribe
6,716,452 Active agent delivery systems and methods for protecting and administering active agents ➤ Subscribe
7,687,466 Abuse-resistant amphetamine prodrugs ➤ Subscribe
7,678,770 Abuse-resistant amphetamine prodrugs ➤ Subscribe
7,375,082 Abuse-resistant hydrocodone compounds ➤ Subscribe
7,662,787 Abuse resistant lysine amphetamine compounds ➤ Subscribe
7,659,254 Abuse-resistant amphetamine prodrugs ➤ Subscribe
7,655,630 Abuse-resistant amphetamine prodrugs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,105,486

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 462411 ➤ Subscribe
Austria 462412 ➤ Subscribe
Austria 519502 ➤ Subscribe
Austria 533512 ➤ Subscribe
Austria 545427 ➤ Subscribe
Australia 2001286599 ➤ Subscribe
Australia 2001297565 ➤ Subscribe
Australia 2001298033 ➤ Subscribe
Australia 2003216382 ➤ Subscribe
Australia 2003217676 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Medtronic
Mallinckrodt
Express Scripts
Johnson and Johnson
Cerilliant
Covington
Daiichi Sankyo
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot